Pfizer Inc. and vaccine partner COVID-19 BioNTech delivered a boost blow late Thursday night specifically targeting the so-called delta variant of the disease-causing virus.
said in a statement that there are encouraging data on the use of a third booster dose of their current BNT162b2 vaccine, which is widely administered in two doses given three weeks apart.
“Although we believe that the third dose of BNT162b2 may maintain the highest protective efficacy against all currently known variants, including delta, we remain vigilant and are developing an updated version of the Pfizer-COVID-19 vaccine using a new design based on line B.1.617.2, which was first identified in India and is also known as the delta variant, ”the companies said in a statement.
Drug manufacturers also pointed this out Evidence from the Israeli Ministry of Health Demonstration of vaccine efficacy fell six months after the techniques, just as the delta variant has taken over the country. Pfizer and BioNTech expect to begin clinical trials for the third dose in August.
“Therefore, we have said and continue to believe that, based on current data, a third dose is likely to be needed 6 to 12 months after full vaccination,” the companies said.
On Thursday, Japan banned spectators from the Tokyo Olympics Due to the increase in COVID cases, which is probably due to the delta variant. Previously, personal participation in the games was prohibited only for foreign viewers.